Page last updated: 2024-11-05

cyclohexanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID7967
CHEMBL ID18850
CHEBI ID17854
MeSH IDM0111080

Synonyms (101)

Synonym
BIDD:ER0292
9003-41-2
smr001224507
MLS002152896
nadone
wln: l6vtj
nsc-5711
anon
ketohexamethylene
cyclohexanon
anone
hytrol o
nci-c55005
hexanon
cicloesanone
pimelin ketone
sextone
nsc5711
pimelic ketone
cykloheksanon
CHEBI:17854 ,
hytrolo
chembl18850 ,
bdbm6
ketocyclohexane
oxocyclohexane
inchi=1/c6h10o/c7-6-4-2-1-3-5-6/h1-5h
CYH ,
NCGC00091786-01
einecs 203-631-1
caswell no. 270
hsdb 186
epa pesticide chemical code 025902
nsc 5711
cykloheksanon [polish]
un1915
cyclohexanon [dutch]
rcra waste number u057
rcra waste no. u057
ai3-00041
ccris 5897
cicloesanone [italian]
108-94-1
C00414
cyclohexanone ,
cyclohexanone, 99.8%
cyclohexanone, reagentplus(r), 99.8%
DB02060
cyclohexanone, acs reagent, >=99.0%
cyclohexanone, puriss. p.a., >=99.5% (gc)
cyclic ketone
BMSE000405
AKOS000119815
NCGC00091786-02
ec 203-631-1
unii-5qor3ym052
cyclohexanone [un1915] [flammable liquid]
5qor3ym052 ,
HMS3039C04
tox21_302750
NCGC00256489-01
cas-108-94-1
dtxcid00359
dtxsid6020359 ,
tox21_202121
NCGC00259670-01
FT-0624193
cyclohexanone [hsdb]
cyclohexanone [inci]
cyclohexanone [iarc]
cyclohexanone [fhfi]
cyclohexanone [mi]
S6236
cylcohexanone
4-cyclohexanone
cylohexanone
cyclo-hexanone
2-cyclohexanone
un 1915
9075-99-4
mfcd00001625
FT-0699543
J-520160
F0001-0185
cyclohexanone, selectophore(tm), >=99.5%
cyclohexanone, jis special grade, >=99.0%
cyclohexanone, saj first grade, >=98.0%
cyclohexanone, puriss., >=99.5% (gc)
cyclohexanone, analytical standard
cyclohexanon(dutch)
cyclohexanone, p.a., 99.0%
cyclohexanone, ar, >=99.5%
cyclohexanone, vetec(tm) reagent grade, 98%
cyclohexanone, lr, >=99%
cyclohexanone 5000 microg/ml in methanol
cyclohexanone acs grade
Q409178
cyclohexanone,(s)
STL183287
EN300-19567
Z104474256

Research Excerpts

Overview

Cyclohexanone is an industrial solvent used as a coupling agent in medical plastics. It is an important intermediate in the manufacture of polyamides in chemical industry. Direct selective hydrogenation of phenol to cyclo hexanone under mild conditions is a challenge.

ExcerptReferenceRelevance
"Cyclohexanone is an industrial solvent used as a coupling agent in medical plastics. "( Association of Neurodevelopmental Outcomes With Environmental Exposure to Cyclohexanone During Neonatal Congenital Cardiac Operations: A Secondary Analysis of a Randomized Clinical Trial.
Bembea, M; Buckley, JP; Ellis, G; Everett, AD; Graham, D; Graham, EM; Griffiths, M; Yang, J, 2020
)
2.23
"Cyclohexanone is a chemical used in various industries and many workers are exposed to it. "( Assessment of cyclohexanone toxicity in inhalation-exposed F344 rats and B6C3F1 mice: applications in occupational health.
Choi, HS; Kim, YS; Lee, YH; Lim, CH; Seo, DS,
)
1.93
"Cyclohexanone is an important intermediate in the manufacture of polyamides in chemical industry, but direct selective hydrogenation of phenol to cyclohexanone under mild conditions is a challenge. "( Highly selective hydrogenation of phenol and derivatives over a Pd@carbon nitride catalyst in aqueous media.
Antonietti, M; Li, H; Su, D; Wang, Y; Yao, J, 2011
)
1.81

Toxicity

ExcerptReferenceRelevance
" Except for transient ataxia and sedation, no adverse effects were observed among neonates that received 3:1 medium- and long-chain triglyceride emulsion for 9 consecutive days beginning on day 3 postpartum."( Assessment of the safety of chemicals administered intravenously in the neonatal rat.
Gillies, B; Greener, Y; Schmitt, D; Wienckowski, D; Woods, E; Youkilis, E, 1987
)
0.27
" Daily observations for signs of toxicity showed no adverse effects in Wistar or Gunn rats injected with either dose."( Assessment of the toxicity of cyclohexanone administered intravenously to Wistar and Gunn rats.
Greener, Y; Indacochea-Redmond, N; Martis, L, 1982
)
0.55

Dosage Studied

ExcerptRelevanceReference
" The administration of DEHP at dosage of 164."( Assessment of the safety of chemicals administered intravenously in the neonatal rat.
Gillies, B; Greener, Y; Schmitt, D; Wienckowski, D; Woods, E; Youkilis, E, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
cyclohexanonesAny alicyclic ketone based on a cyclohexane skeleton and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
cyclohexanol degradation514

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency100.00000.100020.879379.4328AID588453
Smad3Homo sapiens (human)Potency1.99530.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency22.77520.003041.611522,387.1992AID1159552
estrogen nuclear receptor alphaHomo sapiens (human)Potency28.21620.000229.305416,493.5996AID743069; AID743080
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency80.80950.001723.839378.1014AID743083
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency1.45810.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phenylethanolamine N-methyltransferaseBos taurus (cattle)IC50 (µMol)1,000.00000.96005.32008.0000AID155162
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
methylationPhenylethanolamine N-methyltransferaseBos taurus (cattle)
epinephrine biosynthetic processPhenylethanolamine N-methyltransferaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (1)

Processvia Protein(s)Taxonomy
phenylethanolamine N-methyltransferase activityPhenylethanolamine N-methyltransferaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID101345Toxicity determined using Golden Orfe Fish Test1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID155162Inhibitory activity against phenylethanolamine N-methyl-transferase1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Importance of the aromatic ring in adrenergic amines. 5. Nonaromatic analogues of phenylethanolamine as inhibitors of phenylethanolamine N-methyltransferase: role of hydrophobic and steric interactions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (295)

TimeframeStudies, This Drug (%)All Drugs %
pre-199041 (13.90)18.7374
1990's20 (6.78)18.2507
2000's90 (30.51)29.6817
2010's117 (39.66)24.3611
2020's27 (9.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 75.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index75.87 (24.57)
Research Supply Index5.75 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index132.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (75.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.64%)5.53%
Reviews8 (2.56%)6.00%
Case Studies5 (1.60%)4.05%
Observational0 (0.00%)0.25%
Other297 (95.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]